Harrow Health (NASDAQ:HROW) reported quarterly losses of $(0.31) per share. This is a 196.88 percent decrease over earnings of $0.32 per share from the same period last year. The company reported quarterly sales of
November 9, 5:41 AM
Companies Reporting Before The Bell • Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter. • KT (NYSE:KT) is projected to report earnings for its third quarter.
September 22, 12:32 PM
According to Benzinga Pro, during Q2, Harrow Health (NASDAQ:HROW) earned $4.17 million, a 72.13% increase from the preceding quarter. Harrow Health also posted a total of $18.13 million in sales, a 17.43% increase since Q1.
September 2, 8:07 AM
Melt Expects to Dose First Patient in MELT-300 Phase 2 Study During September 2021 NASHVILLE, Tenn.--(BUSINESS WIRE)-- Harrow Health, Inc. (NASDAQ:HROW), an ophthalmic-focused healthcare company, and Melt
August 18, 9:24 AM
For an undisclosed amount, Harrow Health Inc (NASDAQ:HROW) has agreed to acquire MAQ-100 U.S. and Canadian commercial rights from Wakamoto Pharmaceutical Co Ltd. MAQ-100…
Harrow Health Acquires US And Canadian Rights To MAQ-100 From Wakamoto Pharmaceutical; Terms Not Disclosed
August 18, 7:15 AM
Harrow Health, Inc. (NASDAQ:HROW), an ophthalmic‑focused healthcare company, today announced that it has entered into an agreement with Wakamoto Pharmaceutical Co., Ltd. to acquire the U.S. and Canadian commercial rights
August 10, 4:15 PM
Harrow Health (NASDAQ:HROW) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.03) by 266.67 percent. This is a 1000 percent decrease over losses of $(0.01) per share from